After three years in the bundled joint replacement business, a federal policy shift is prompting Medtronic to put its Responsive Orthopedics business on the auction block.
The May 2016 acquisition of Minneapolis-based Responsive for an undisclosed amount put Medtronic in line for a bundled joint replacement program piloted by the Centers for Medicare & Medicaid Services.
The 5-year “Comprehensive Care for Joint Replacement” program originally involved more than 800 hospitals in 75 geographic areas, covering the procedures from hospital admission to 90 days after discharge. Soon after the Responsive buyout, Fridley, Minn.-based Medtronic rolled out a new Orthopedic Solutions business expressly to take advantage of the CCJR program.
But CMS made the program voluntary in November 2017, prompting participating hospitals to opt out. That shrinking market, combined with the competitive pricing in the joint replacement market, pushed Medtronic into abandoning the field.
“In February 2019, Medtronic announced that it was withdrawing from the orthopedic implant market. This decision was made in response to shifting market dynamics and to focus the business for future growth,” a spokeswoman told MassDevice.com via email. “Since the company acquired Responsive Orthopedics in 2016, federal guidelines for orthopedic joint replacement have shifted and implant pricing has become highly competitive, making it difficult for Medtronic to offer a disruptive solution. The Responsive Orthopedic knee system remains a high-quality, effective implant that has performed well for the patients who received it. Medtronic is focused on superior product quality, and our orthopedic implants are no exception.”
The company did not respond to more specific questions about the Responsive Orthopedics sale.
2016年5月， Medtronic 以未披露的金额收购了明尼阿波利斯的 Responsive ，这使得美敦力（Medtronic）有望推出由医疗保险和医疗补助服务中心( Centers for Medicare & Medicaid Services )试点的捆绑联合替代计划。
为期5年的“联合替代综合护理”项目原涉及75个地理区域的800多家医院，涵盖从住院到出院90天的程序。在回应收购后不久，明尼苏达州弗里德利。-美敦力（Medtronic）公司推出了新的骨科解决方案业务，明确利用 CCJR 计划。
但 CMS 在2017年11月自愿加入该计划，促使参与计划的医院选择退出。市场萎缩，再加上联合置换市场的竞争性定价，促使美美敦力（Medtronic）放弃该领域。
“2019年2月，美美敦力（Medtronic）宣布退出骨科植入市场。一位发言人对 MassDevice 表示：“这一决定是为了应对不断变化的市场动态，并将业务重点放在未来的增长上。”通过电子邮件。“自2016年公司收购 Responsive Orthodotics 以来，联邦骨科联合置换指导方针发生了变化，植入定价竞争激烈，使得美美敦力（Medtronic）难以提供颠覆性解决方案。响应骨科膝关节系统仍然是一种高质量、有效的植入物，对接受它的患者表现良好。美美敦力（Medtronic）专注于卓越的产品质量，我们的骨科植入物也不例外。”